The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended the granting of a marketing authorization for an adapted vaccine against COVID-19 targeting the XBB.1.5 subvariant.
The vaccine is produced by Pfizer/BioNTech and Bulgaria will receive 1.3 million doses of it after it is approved for use by the European Commission. Our country has guaranteed access to adapted vaccines by virtue of Supplementary Agreement No. 5 to the Agreement on the purchase, further development, production and options for the purchase and supply of a vaccine against COVID-19 for EU member states.
The first delivery of 80,640 doses is planned for the third week of September. The vaccines we expect to arrive then are indicated for use in adults and persons 12 years of age and older.
Delivery of pediatric vaccines intended for the immunization of children from 6 months to 11 years of age is also planned for the last week of September.
Vaccines will continue to be administered free of charge to Bulgarian citizens who request it from their general practitioner, in the immunization offices of the RZI and in designated medical facilities.
In the next week, the National Expert Council on Immunizations is expected to make its recommendations to the Minister of Health on the vaccination against COVID-19 of the risk groups of the population.
Additional information about the adapted Comirnaty vaccine can be found on the website of the Executive Medicines Agency – bda.bg.
2023-08-31 14:16:20
#EMA #approved #adapted #vaccine #COVID19 #Bulgaria #receive #million #doses
